Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. - Wikidata - awgldk - TriplyDB

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.

http://www.wikidata.org/entity/Q44762080

about

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies Non-steroidal anti-inflammatory drugs for acute gout Systemic corticosteroids for acute gout Gout--current diagnosis and treatment Taking the stress out of managing gout EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)The safety of rofecoxib Hepatic gene expression response to acute indomethacin exposure Etoricoxib: a highly selective COX-2 inhibitor.Management of hyperuricemia in gout: focus on febuxostat.Colchicine for the treatment of gout.Clinical pharmacology of etoricoxib.Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.Etoricoxib for arthritis and pain management Acute gout: oral steroids work as well as NSAIDs Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.An update on the treatment options for gout and calcium pyrophosphate deposition.Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.A Randomized, Controlled Trial to Assess the Efficacy of Arthroscopic Debridement in Combination with Oral Medication Versus Oral Medication in Patients with Gouty Knee Arthritis.Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial.2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.Management of gout.Gout. Novel therapies for treatment of gout and hyperuricemia.Gout--what are the treatment options?Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.Managing your patient with gout: a review of treatment options.The challenges of gout management in the elderly.Difficult-to-treat gouty arthritis: a disease warranting better management.Canakinumab in gout.Outcome measures in acute gout: a systematic literature review.Optimizing current treatment of gout.Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review.Advances in pharmacotherapy for the treatment of gout.Enhanced analgesic activity by cyclodextrins - a systematic review and meta-analysis.Current and future therapies for gout.Update on colchicine, 2017.Foot pain, impairment, and disability in patients with acute gout flares: A prospective observational study.Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)

P2860

Q21144617-0AA4E544-A508-402C-BC67-8D6892131FD8 Q24193584-59138FF9-7EC6-4685-B0D6-16C96B870F26 Q24243127-44A28530-F4CF-435D-85CA-0B15F6F6CA48 Q24644156-71A68409-E18F-4294-A12F-2518CB878B20 Q24658037-DF9AACA1-3E19-40BB-B273-F77DE149246F Q24675150-04A1A343-ADBE-4999-AED6-2EB2B0AC698D Q28176535-548D6032-25CC-43F9-B148-6D2C0F568BE5 Q29144218-D5E5C2BE-CC2B-4D40-AE1B-B5E7A6B3E042 Q33213983-EB084AD4-92CC-492E-9A32-AFF88C8B4555 Q33635542-4B811F64-8BD3-4748-A2AB-17C3DC60343E Q33738046-29AB6F34-ADF3-4B6C-B1A3-8BF42CA40244 Q34570225-D999E7DA-89DA-41F0-A313-EE25CC688B7E Q35092969-A36D3589-0926-43AE-830E-8D1E96B2F58A Q35166773-E2A69986-2892-43BA-BB04-57377E7F4ACF Q35246568-BDC38954-1BEB-4AA1-9425-7415D64E5ECA Q35671108-F8E4DBCF-AE88-40D6-B110-190D37029DBB Q36013803-3FCD885E-E16C-4810-943A-612C018595BD Q36301585-1D2F0384-383A-4D08-B2FE-D1312C041087 Q36349740-981C43ED-5F9D-4CEB-A808-473DCEDA1DAF Q36408778-CD1DB98A-4368-4565-8D27-E551D12A8197 Q36685004-2F386705-BE93-4C43-8ADC-3CBF45A66CB0 Q36870924-1B1AA14A-53B8-4697-93BC-2328A6C8D519 Q36903272-81012C89-3785-431A-8C44-82A9C894601D Q37139512-6B6BF814-150D-476B-9956-6423228083AA Q37350841-FDE697C0-930C-4443-BD01-13545E2A5B0C Q37492596-DA8E8003-7DCC-4374-90C0-23B7298D704A Q37553140-69B33135-0C75-4E0C-8B17-8A10B7ED9BE2 Q37874889-9C5B671E-6516-4B07-992B-72A196D77971 Q37910891-7D0C75AB-7FB2-4F73-87D3-6DCB3A994DAC Q37910901-C2D4A888-DAF6-4E76-89C1-9BE093AE69B3 Q38025456-97191C40-3F5D-488E-B0C4-EC9C575DEBF7 Q38170977-6977AFF5-0D4D-413B-9DD3-EE0821D6C74F Q38194896-48E42ADA-B97D-4A8D-A62D-52173A3775E2 Q38268302-0F2A2B24-D4CA-42D6-AEEF-30A677230169 Q38303416-F6E59E5E-D43F-4933-A420-88F3A650A726 Q38544457-BC2754C2-7FEB-4F59-9BBF-78587D08E2E6 Q38660829-E5776494-5748-4722-BC0A-DB7E828E7C28 Q47177948-2790FE2B-ACA3-44F5-87C7-35182310A2DC Q52844811-07F25F89-95F1-4784-A980-C7EC5F480ADA Q56637250-4CEB608D-B835-443A-9B68-1AD4976985B3

P2860

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.

http://www.wikidata.org/entity/Q44762080

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Efficacy and safety profile of ...... a randomized controlled trial.

@en

Efficacy and safety profile of ...... a randomized controlled trial.

@nl

type

label

Efficacy and safety profile of ...... a randomized controlled trial.

@en

Efficacy and safety profile of ...... a randomized controlled trial.

@nl

prefLabel

Efficacy and safety profile of ...... a randomized controlled trial.

@en

Efficacy and safety profile of ...... a randomized controlled trial.

@nl

P1433

Q44762080-C57AA693-DB73-47D5-AFE7-EF28B9BD1384

P1476

Q44762080-6BF05FFF-848D-46D4-A4DA-42400366D28D

P2093

Q44762080-1A901D6F-0F2E-4E49-B836-27611AA18A91

Q44762080-2084454B-B987-4964-9CD5-04E38BFBC390

Q44762080-24C3CB99-5B8A-474D-A66D-92C79F4C9C71

Q44762080-2E8BE928-F044-4DB8-A075-C1A480262010

Q44762080-40115EB4-F31B-4797-BA1B-743351323297

Q44762080-76C38938-FADD-4D26-AB8A-86B9FE8E466C

Q44762080-A6A689A0-8172-4DBD-AA0C-C69F83AB8091

Q44762080-ADBCC282-5082-4820-A7A7-88FD73C52929

Q44762080-AE6F102C-EF7B-4917-9D7D-DBCEEF34AECB

Q44762080-B186CCF2-8078-442F-9A23-0B806D33805B

P2860

Q44762080-0033CB5D-104D-46FC-AF69-90CACACDF2EE

Q44762080-29F7DC48-955D-4D8D-99D0-5AF7C9A33112

Q44762080-2C85FCBA-70A3-46DA-A37C-3F6AD57D8A9E

Q44762080-38A34326-67CF-4282-8E46-6A7A6BC2757C

Q44762080-90EA01AE-FDB2-4A7F-9C80-92D3C847334C

Q44762080-B144CB32-E762-4861-AD58-C9F3F26A648D

Q44762080-B289AB77-220E-4AEE-9C68-D7F4CA8E6FCA

Q44762080-BC1973D1-5E71-4335-BAC6-884E498C2C46

Q44762080-F6AAFDAA-525C-4065-8901-469553AE4B14

Q44762080-FCDB1AF9-8233-49B7-A18B-5084F5B38B99

P304

Q44762080-8438D7EF-E3CC-43CE-8D15-A72FA341E871

P31

Q44762080-774AAFED-F1B3-412C-803B-1FE0BD8C0B41

P356

Q44762080-E7558C70-3D64-45D7-ABA4-6B6F45614A36

P433

Q44762080-0755B955-ED63-4B19-96D4-39879AE16E6D

P478

Q44762080-1114E4D0-EAE8-4E4E-A996-6135765C60A5

P577

Q44762080-08ACAC8C-961F-4F96-92EA-377BBFDD6AA5

P5875

Q44762080-ED41EA96-6D5B-4498-B9D4-2296EFBC7908

P698

Q44762080-965B3BA4-C3C6-4E7A-9B71-EA566A6C255C

P356

P1433

Arthritis & Rheumatology

P1476

Efficacy and safety profile of ...... a randomized controlled trial.

@en

P2093

Bernard R Rubin

http://www.w3.org/2001/XMLSchema#string

Daryl K Najarian

http://www.w3.org/2001/XMLSchema#string

Erluo Chen

http://www.w3.org/2001/XMLSchema#string

Gregory P Geba

http://www.w3.org/2001/XMLSchema#string

John Londoño

http://www.w3.org/2001/XMLSchema#string

Joseph Antigua

http://www.w3.org/2001/XMLSchema#string

Keith G Pryhuber

http://www.w3.org/2001/XMLSchema#string

Margaret Lund

http://www.w3.org/2001/XMLSchema#string

Richard A Petruschke

http://www.w3.org/2001/XMLSchema#string

Robert Burton

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

Gastrointestinal effects of nonsteroidal anti-inflammatory therapy.

Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications.

Comparative toxicity of nonsteroidal anti-inflammatory drugs.

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.

The management of gout.

Crystal-induced arthritis: an overview.

Review article: COX-II inhibitors--a new generation of safer NSAIDs?

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.

P304

598-606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.20007

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8777059

http://www.w3.org/2001/XMLSchema#string

P698

14872504

http://www.w3.org/2001/XMLSchema#string